These agents are thought to improve hepatic insulin sensitivity and reduce liver fat content, potentially lowering the progression to steatohepatitis and cirrhosis.[39,40] Collectively, these findings underscore the expanding therapeutic potential of SGLT2 inhibitors in managing cardiovascular, renal, and hepatic comorbidities, positioning them as versatile agents in clinical practice. The gene discussed is SLC5A2; the disease is Cirrhosis.